替加环素治疗耐药鲍氏不动杆菌肺炎的疗效研究

发布时间：2018-12-25 12:20

【摘要】：目的探讨替加环素对泛耐药鲍氏不动杆菌(XDRAB)或多耐药鲍氏不动杆菌(MDRAB)肺炎治疗的临床效果,为XDRAB或MDRAB肺炎治疗提供理论依据。方法分析2013年5月-2015年2月医院重症医学科(ICU)接受治疗的48例XDRAB或MDRAB感染患者的临床资料,对患者的病死率、细菌清除率以及临床有效率进行观察和比较,数据采用SPSS 19.0软件进行统计分析。结果 48株鲍氏不动杆菌对碳青霉烯类药物有极高的耐药性,耐药率均为100.00%;治疗后,鲍氏不动杆菌清除24株,清除率为50.00%,治疗有效24株,有效率为50.00%。结论常规抗耐药ABA感染的治疗失败后,可以尝试将替加环素作为一种抢救性的治疗选择,然而临床上还需更多更可靠的证据。
[Abstract]:Objective to investigate the clinical efficacy of tegicycline in the treatment of pan-resistant Acinetobacter baumannii (XDRAB) or multidrug resistant Acinetobacter baumannii (MDRAB) pneumonia, and to provide a theoretical basis for the treatment of XDRAB or MDRAB pneumonia. Methods the clinical data of 48 patients with XDRAB or MDRAB infection who were treated by (ICU) from May 2013 to February 2015 were analyzed. The mortality rate, bacterial clearance rate and clinical effective rate were observed and compared. The data were analyzed by SPSS 19.0 software. Results 48 strains of Acinetobacter baumannii showed very high resistance to carbapenem, the drug resistance rate was 100.000.After treatment, 24 strains of Acinetobacter baumannii were cleared, the clearance rate was 50.00g and the effective rate was 50.00g. Conclusion after the failure of routine anti-drug-resistant ABA infection, we can try to treat tigicycline as a kind of rescue treatment option, but more and more reliable evidence is needed in clinic.
【作者单位】：奉化市人民医院ICU;
【基金】：浙江省科技厅基金资助项目(2008C13029.1)
【分类号】：R563.1

【相似文献】